Overview

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study will test the feasibility of combining 3 drugs, Revlimid with Doxil and Bevacizumab,and gather preliminary data on the potential activity of the combination in patients with platinum resistant/refractory ovarian cancer.
Phase:
Phase 1
Details
Lead Sponsor:
New Mexico Cancer Care Alliance
Collaborator:
Celgene Corporation
Treatments:
Bevacizumab
Doxorubicin
Lenalidomide
Liposomal doxorubicin
Thalidomide